背景介绍 CD155 is a transmembrane glycoprotein receptor belonging to the immunoglobulin superfamily. It is highly expressed on dendritic cells, fibroblasts, endothelial cells, and multiple tumor cells including ovarian carcinoma, non-small cell lung, glioblastoma, and colorectal carcinoma. It has a high affinity for a T cell regulatory transmembrane surface protein called TIGIT (T cell immunoglobulin and ITIM domains), and plays a key role in tumor cell invasion and migration. Interaction between CD155 and TIGIT causes immunosuppressive effects on CD4+ and CD8+ T cells, which hinders T cell proliferation and function. CD155 also interacts with regulatory receptors CD226 (expressed on natural killer (NK) cells, monocytes and CD4+ T cells) and CD96. While CD155-CD226 engagement activates NK cell cytotoxicity and T cell response, CD155-CD96 interaction inhibits NK cell function. Due to these opposing regulatory effects, blockade of CD155-TIGIT and CD155- CD226 interactions are attractive therapeutic strategies in cancer immunotherapy and autoimmune diseases, respectively. 产品介绍 Recombinant HEK293 cell line expressing full length human CD155, also known as poliovirus receptor (PVR) or nectin-like molecule-5 (NECL-5). Expression is confirmed by Western Blot.